News und Analysen
5 Supernova Stocks That Have Flown Under the Radar: NuVasive
Last week on the Rule Breaker Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....
Is Opko Health Inc. a Buy?
Longtime Opko Health Inc. (NASDAQ: OPK) shareholders have a lot to be upset about. Using about $1.47 billion of its own stock to acquire a big lab service provider a couple years ago was supposed....
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3....
Is Valeant Turning Things Around?
Valeant Pharmaceuticals (NYSE: VRX) is notorious for its drug price gouging scandal a few years ago, an incident that caused the stock to tank and public opinion of the company plummeting to hit....
Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported....
Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
Bayer AG (NASDAQOTH: BAYRY) has entered into a collaborative partnership with Loxo Oncology (NASDAQ: LOXO) that could make it a global leader in cancer drugs that are used in patients based on....
5 Supernova Stocks That Have Flown Under the Radar
Recently on the Rule Breakers Investing podcast, Motley Fool co-founder David Gardner reviewed the performance of two sets of his buy-and-hold stock picks: one set with a five-year horizon, and....
Why Sears Holdings, Immunomedics, and J.C. Penney Slumped Today
Monday was a good day for the stock market, with major benchmarks finishing with modest gains to sustain the generally bullish sentiment among investors. Some investors remain uncertain about....
Why Roku, GGP, and Nektar Therapeutics Jumped Today
The stock market got off to a solid start on Monday, bouncing back from small losses early in the trading day to finish with modest gains. Major benchmarks were up less than a quarter percent as....
Why Nektar Therapeutics Shares Are Rallying 13.8% Today
After the company presented results from an early-stage study of its NKTR-214 in solid tumor cancer at the 2017 Society for Immunotherapy of Cancer (SITC) annual meeting, Nektar Therapeutics....
Qiagen NV Meets Its Own 3rd-Quarter Expectations
Qiagen (NASDAQ: QGEN) reported third-quarter earnings in line with its revenue and earnings guidance, which disappointed investors who have come to expect earnings beats.MetricQ3 2017Continue....
Will Invitae Ever Turn a Profit?
Genetic-testing leader Invitae (NYSE: NVTA) has promised to usher in a new age of healthcare, one influenced by every individual's unique genetic profile. To do so, it's ditching the industry's....
A Rare Quarterly Appearance by bluebird bio Inc.'s Management
bluebird bio (NASDAQ: BLUE) released third-quarter earnings complete with a conference call, which the biotech doesn't usually hold for quarterly results, but this quarter was different with....
3 Top Healthcare Stocks to Buy in November
At 14.1%, healthcare is the third largest weighted sector in the S&P 500 index, and with 76 million baby boomers getting older and living longer, owning healthcare stocks in your portfolio....
Evotec: Nur eine Korrektur oder droht Schlimmeres?
Irgendwann trifft es auch die beste Aktie. In der letzten Handelswoche war nun Evotec an der Reihe. Nach einer monatelangen Rally ab Februar 2016 im Zuge derer der Kurs Bitcoin-artig um fast 700 %....
Better Buy: Exelixis, Inc. vs. Novartis AG
Novartis (NYSE: NVS) stands out as one of the biggest pharma companies with a broad array of products, including several of the most powerful cancer drugs on the market. Exelixis (NASDAQ: EXEL)....
3 Biotech Stocks That Soared This Week: Are They Buys?
Earnings season continued to be in high gear this week. Positive quarterly results helped propel several biotech stocks higher over the last few days. Others jumped because of good news for their....
Why Immunomedics, Inc. Jumped Higher Today
Immunomedics (NASDAQ: IMMU) is up 19% at 2:21 p.m. EST, after announcing a new CEO following the closing bell yesterday. The company also announced fiscal first-quarter earnings, but the jump in....
Ionis Pharmaceuticals' Earnings Results Fuel Volatility
Ionis Pharmaceuticals (NASDAQ: IONS) reported third-quarter financials that were better than hoped on Tuesday, but the worry of slowing U.S. sales of Spinraza, a rare disease drug that's licensed....
Why Macy's, Hostess Brands, and Perrigo Jumped Today
The stock market lost ground Thursday as investors reacted negatively to news regarding proposed U.S. corporate and individual income tax cuts. Reports surfaced that the Senate version of tax....
The Not-So-Subtle Reason Behind Perrigo Company PLC's 13% Move Higher
Shares of Perrigo (NYSE: PRGO), a provider of consumer goods and over-the-counter pharmaceutical products, rocketed higher by as much as 13% during Thursday's trading session after the company....
2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why.
Shares of SAGE Therapeutics Inc. (NASDAQ: SAGE) are rocketing higher today in response to positive clinical trial data for a postpartum depression candidate. Investors are pushing up Marinus....
This Gene Therapy Can Restore Vision, but Will It Break the Bank?
In October, Spark Therapeutics (NASDAQ: ONCE) took another step closer to FDA approval for its vision-restoring drug, Luxturna. An approval for the gene-editing therapy early next year would be a....
Globus Medical Inc. Posts Solid 3rd-Quarter Results With Robots in Its Future
Globus Medical Inc. (NYSE: GMED) shareholders had to love the first half of 2017. The musculoskeletal-solutions company saw its stock price soar more than 30% by late June. Since then, Globus....
Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drug developer that's primarily grown through price hikes and acquisitions over the years, tumbled 18% during October, according to data....